End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.85 NZD | -0.21% | +0.63% | +22.25% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 65.35 and 50.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.25% | 10.3B | B+ | ||
-6.02% | 180B | C+ | ||
+3.19% | 112B | C | ||
-2.74% | 68.53B | A | ||
+5.52% | 51.97B | B- | ||
+6.94% | 44.08B | B- | ||
+5.62% | 42.23B | B+ | ||
+23.59% | 32.43B | B | ||
+16.72% | 26.39B | A- | ||
-2.95% | 24.97B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FPH Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited